Philippe Busque's most recent trade in Cytek BioSciences Inc was a trade of 2,946 Common Stock done . Disclosure was reported to the exchange on March 10, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,946 | 17,067 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,946 | 26,521 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,049 | 14,920 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,049 | 12,810 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 1,148 | 15,919 | - | 4.4 | 5,005 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 799 | 14,121 | - | 4.4 | 3,484 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 91,911 | 91,911 | - | - | Employee Stock Option (right to buy) | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 58,004 | 58,004 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,210 | 29,467 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,210 | 13,732 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,536 | 14,859 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,536 | 12,121 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 861 | 12,871 | - | 6.0 | 5,192 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 599 | 11,522 | - | 6.0 | 3,612 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 2,210 | 31,677 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 2,210 | 11,446 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,536 | 9,835 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,536 | 16,395 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 861 | 10,585 | - | 5.5 | 4,761 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 599 | 9,236 | - | 5.5 | 3,312 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,659 | 17,931 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,659 | 9,994 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 2,594 | 7,400 | - | 6.0 | 15,460 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,473 | 33,887 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,473 | 8,873 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 574 | 8,299 | - | 6.0 | 3,421 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 5,464 | 0 | - | - | Restricted Stock Units | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 5,464 | 5,464 | - | - | Common Stock | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.70 per share. | 20 Mar 2024 | 2,129 | 3,335 | - | 6.7 | 14,264 | Common Stock |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 52,631 | 52,631 | - | - | Employee Stock Option (right to buy) | |
Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 35,360 | 35,360 | - | - | Restricted Stock Units |